Vous êtes ici

Quantum BioPharma Ltd. Subordinate Voting Shares

Liste d'échange: 
CSE
Statut: 
Active
Industrie: 
Life Sciences
Symbole: 
QNTM
Indice CSE: 
Devise: 

Quantum BioPharma Ltd. is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. ("Lucid"), Quantum is focused on the research and development of its lead compound, Lucid-MS (formerly Lucid-21-302) ("Lucid-MS"). Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum invented unbuzzd™ and spun it out its OTC version to a company, Celly Nutrition, led by industry veterans. Quantum retains ownership of 25.71% (March 31, 2024) of Celly Nutrition Corp. at www.cellynutrition.com. The agreement with Celly Nutrition also includes royalty payments of 7% of sales from unbuzzd ™ until payments to Quantum total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Additionally, Quantum retains a large tax loss carry forward of approximately CAD$130 million and could be utilized in the future to offset tax payable obligations against future profits. Quantum retains 100% of the rights to develop similar product or alternative formulations specifically for pharmaceutical / medical uses. FSD Pharma maintains a portfolio of strategic investments through its wholly owned subsidiary, Quantum Strategic Investments Inc., which represent loans secured by residential or commercial property.

Vous êtes ici

Quantum BioPharma Ltd. Subordinate Voting Shares (QNTM)

SEDAR Information

Information d'entreprise

Addresse
199 Bay Street
Suite 4000
Toronto, ON M5L 1A9
Canada
Téléphone
844-978-3540
Courriel
info@fvpharma.com
URL
http://www.quantumbiopharma.com
Date d’inscription à la cote
Mardi, mai 29, 2018
Agent de transfert
Marrelli Trust Company Limited
Relations avec les investisseurs
Zeeshan Saeed
Courriel
ir@quantumbiopharma.com
Vérificateur
MNP LLP

Capitalisation

Capitalisation: 
1919400
Réservé à l'émission: 
172825

Company Officers

Anthony Durkacz, Founder & Executive Co-Chairman
Zeeshan Saeed, Founder & Executive Co-Chairman

Communiqués de presse

Bulletins

13/08/2024

2024-0813 – Changement du Nom et du Symbole et Consolidation - FSD Pharma Inc. Class B Subordinate Voting Shares (HUGE)

le 13 août/August 2024

FSD Pharma Inc. Class B Subordinate Voting Shares (HUGE) has announced a name and symbol change to Quantum BioPharma Ltd. Class B Subordinate Voting Shares (QNTM) and a consolidation of its issued and outstanding subordinate voting shares on the basis of one (1) post-consolidated subordinate voting share for every sixty five (65) pre-consolidated subordinate voting shares.